Join HELLO! as we take a look back at Chrissy Metz's incredible journey, from her childhood struggles to her new era of self-love.

The New York Times wants to know how a GLP-1 medication may have affected how readers plan vacations. By Betsy Blumenthal Betsy Blumenthal is a senior staff editor on the Travel desk. The indulgence ...

Valeo Health brings testing, doctor-led care, app-based tracking, and medication delivery together in one continuous weight-management programme ...

"Eighty-four percent of households with GLP-1 users visit McDonald's. This is an opportunity," McDonald's USA president Skye ...

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their ...

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, ...

Some of the companies that produce GLP-1 drugs like Ozempic and Zepbound are facing lawsuits alleging that the drugs caused ...

Health headlines for Wednesday, Sept. 23 include GLP-1 vision loss lawsuits, a new Alzheimer's brain map and ibogaine under ...

She was taking a GLP-1 drug to lose weight when she woke up one morning with vision loss in her right eye. Here’s what ...

A. 연구 브리핑GLP-1 수용체 작용제(GLP-1 receptor agonist)는 제2형 당뇨병이나 특정 기준을 충족하는 비만 환자에게 사용되는 약물이다. 그러나 승인된 적응증(약물을 사용하도록 허가된 질환이나 상태)이 명확하지 않은 성인에게도 처방되는 사례가 늘고 있다. 이 집단에서는 약물 사용의 이득과 위험이 아직 분명하지 않다는 점이 문제로 제기된 ...

Patients filed lawsuits against manufacturers of GLP-1 medications, including Ozempic and Wegovy, alleging the drugs caused non-arteritic anterior ischemic optic neuropathy and permanent vision loss.

Across cosmetic and dermatology clinics, a new patient profile is becoming increasingly familiar. Someone who has lost a significant amount of weight on a GLP-1 medication and is thrilled with the ...